Zhejiang Medicine Co Ltd (600216) — Capital Reinvestment Ratio
Zhejiang Medicine Co Ltd (600216) has a Capital Reinvestment Ratio of 0.12x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥690.77 Million) in capital expenditures (CN¥80.03 Million). See 600216 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Medicine Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Zhejiang Medicine Co Ltd's Capital Reinvestment Ratio across 27 annual periods. Check Zhejiang Medicine Co Ltd (600216) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Zhejiang Medicine Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Medicine Co Ltd from 1998 to 2025. For live market cap and broader valuation context, see 600216 market cap.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.24x | CN¥1.89 Billion | CN¥446.47 Million | ▼ -58.0% |
| 2024 | 0.56x | CN¥1.22 Billion | CN¥689.14 Million | ▼ -55.2% |
| 2023 | 1.26x | CN¥634.31 Million | CN¥796.87 Million | ▼ -33.0% |
| 2022 | 1.87x | CN¥520.60 Million | CN¥975.99 Million | ▲ +126.8% |
| 2021 | 0.83x | CN¥1.14 Billion | CN¥939.60 Million | ▲ +94.1% |
| 2020 | 0.43x | CN¥1.26 Billion | CN¥535.35 Million | ▼ -66.8% |
| 2019 | 1.28x | CN¥447.25 Million | CN¥573.63 Million | ▲ +69.3% |
| 2018 | 0.76x | CN¥579.91 Million | CN¥439.30 Million | ▼ -33.1% |
| 2017 | 1.13x | CN¥503.47 Million | CN¥569.99 Million | ▼ -0.3% |
| 2016 | 1.14x | CN¥336.14 Million | CN¥381.76 Million | ▼ -83.3% |
| 2015 | 6.80x | CN¥106.54 Million | CN¥724.96 Million | ▲ +277.3% |
| 2014 | 1.80x | CN¥549.90 Million | CN¥991.76 Million | ▼ -0.5% |
| 2013 | 1.81x | CN¥655.09 Million | CN¥1.19 Billion | ▲ +54.8% |
| 2012 | 1.17x | CN¥807.49 Million | CN¥945.50 Million | ▲ +210.2% |
| 2011 | 0.38x | CN¥912.75 Million | CN¥344.58 Million | ▲ +240.6% |
| 2010 | 0.11x | CN¥1.32 Billion | CN¥145.90 Million | ▲ +6.0% |
| 2009 | 0.10x | CN¥1.47 Billion | CN¥153.13 Million | ▼ -3.7% |
| 2008 | 0.11x | CN¥1.20 Billion | CN¥130.27 Million | ▼ -83.9% |
| 2007 | 0.67x | CN¥227.67 Million | CN¥153.37 Million | ▼ -54.3% |
| 2006 | 1.47x | CN¥169.51 Million | CN¥249.99 Million | ▼ -89.2% |
| 2005 | 13.60x | CN¥25.14 Million | CN¥341.93 Million | ▲ +910.5% |
| 2004 | 1.35x | CN¥107.60 Million | CN¥144.80 Million | ▼ -32.2% |
| 2003 | 1.98x | CN¥66.20 Million | CN¥131.37 Million | ▼ -78.5% |
| 2002 | 9.25x | CN¥23.13 Million | CN¥213.81 Million | ▲ +654.2% |
| 2001 | 1.23x | CN¥98.25 Million | CN¥120.44 Million | ▼ -89.5% |
| 2000 | 11.69x | CN¥10.58 Million | CN¥123.69 Million | ▲ +435.0% |
| 1998 | 2.18x | CN¥57.72 Million | CN¥126.08 Million | — |